No Data
No Data
Tiancong (301263.SZ): Full-owned subsidiary receives registration of two functional carrier auxiliary materials.
On July 17th, Gelunhui reported that its wholly-owned subsidiary Shandong Huabokai Sheng Biotechnology Co., Ltd. (hereinafter referred to as "Huabokai Sheng") recently received the left-handed polylactic acid medical instrument main document registration receipt issued by the Medical Instrument Technical Evaluation Center of the National Medical Products Administration (hereinafter referred to as the "National Drug Administration "); and the registration of methoxy polyethylene glycol-poly glutamic acid sodium (for injection) issued by the Drug Evaluation Center of the National Drug Administration as a pharmaceutical excipient.
Tianchang (301263.SZ): Huapu Kaisheng's lidocaine procaine aerosol clinical trial application has been approved.
On July 16th, Globenews announced that its wholly-owned subsidiary, Shandong Huabao Kaisheng Biotechnology Co., Ltd. (abbreviated as "Huabao Kaisheng"), recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, which agreed to approve Huabao Kaisheng's application for clinical trial of lidocaine and prilocaine aerosol. Lidocaine and prilocaine aerosol are a local anesthetic mainly used for the treatment of primary premature ejaculation in adult men, with clear clinical efficacy and convenient use. The original drug was developed by Plethora, a UK company, and was approved for marketing in the EU in 2013.
Tiankang (301263.SZ) has cumulatively spent 38,986,900 yuan to repurchase 1,985,100 shares.
On July 2nd, Gelonhui reported that Tainkang (301263.SZ) announced that as of June 30, 2024, the company has repurchased a total of 1,985,118 shares through the Shenzhen Stock Exchange trading system using centralized auction trading, accounting for 0.4665% of the company's total share capital. The highest transaction price for the repurchase was 20.12 yuan/share, the lowest was 18.56 yuan/share, and the total amount paid was RMB 38,986,900 (excluding transaction fees).
Tiancong (301263.SZ): The first subject completed the Phase III clinical trial of Huabo Kaisheng's hydrochloride Mao Guoyuxiang alkaline eye drops.
On June 26th, Gelunhui reported that Shandong Huabokai Sheng Biological Technology Co., Ltd. (referred to as "Huabokai Sheng"), a wholly-owned subsidiary of Guangdong Tienkang Medical Technology Co., Ltd., organized the completion of the first subject in the Phase III clinical trial of tropicamide hydrochloride eye drops for adult presbyopia patients. The Phase III clinical trial of tropicamide hydrochloride eye drops is a randomized, multicenter, double-blind, placebo-controlled clinical trial for the effectiveness and safety of adult presbyopia patients, led by the director of the Department of Ophthalmology at Beijing Tongren Hospital affiliated to Capital Medical University, who enjoys special government allowances from the State Council.
Shareholder Julande of Tianencong (301263.SZ) reduced their shares by 790,100 shares with the end of the shareholding period.
Zhichuang Finance and Economics APP News, Tienkang (301263.SZ) announced that as of June 18, 2024, shareholder Julande's time for this shareholding reduction plan has expired. It has sold a total of 790,100 shares and the reduction ratio is 0.1866%.
Tiancong (301263.SZ): CKBA ointment, a Class 1 innovative drug in Borchuang Park, has completed 50% of the subjects according to the Phase II clinical trial plan.
On June 17th, Gelon Hui announced that recently, Guangdong Tian'en Kang Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (Bochuangyuan), a subsidiary of Tian'en Kang (301263.SZ), has organized clinical trials for type 1 innovative drug CKBA ointment for the treatment of vitiligo indications. 50% of the subjects for Phase II clinical trials have been enrolled according to the plan. CKBA can dose-dependently inhibit the catalytic activity of acetyl-coenzyme A carboxylase (ACC1/ACC2) and has good anti-inflammatory and immunomodulatory activity. Inflammatory cytokines are closely related to the pathogenesis of many skin diseases. Self
No Data